The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor

Inclusion Criteria

• •1. Patients aged at or over 45 years old.
• •2. Patients who with one or more of the following situations:
• •1. In AFP (\>20UG/L), CA125 (\>70U/ml), CEA (\>7ng/ml) and CA199 (\>60U/ml), more than one item was abnormal for two consecutive times within one month.
• •2. Patients with viral hepatitis (Hepatitis B / C surface antigen positive with liver function damage.
• •3. Patients with liver nodules detected by ultrasound and hemangioma excluded.
• •4. Patients with compensated cirrhosis.
• •5. CA125\>35U/ml and HE4 was abnormal (the reference value of HE4 in premenopausal and postmenopausal women was 68.96 pmol/L and 114.90 pmol/L respectively).
• •6. Patients with ovarian masses found by ultrasonography (premenopausal \> 5cm, postmenopausal \> 3.5cm).
• •7. Patients with pancreatic space-occupying found by ultrasonography.
• •8. Patients with BI-RADS grade 4 or above by ultrasound or mammography.
• •9. CA125\>35U/ml and BI-RADS above grade 3 by ultrasound or mammography.
• •10. CA153\>25U/ml and BI-RADS above grade 3 by ultrasound or mammography.
• •11. Family genetic history of breast cancer and ovarian cancer, and BI-RADS above grade 3 by ultrasound or mammography.
• •12. Patients with a positive fecal occult blood test and haemorrhoids excluded
• •13. Patients with a positive fecal occult blood test and positive CEA
• •14. More than 2 items were abnormal in PGI, PGR and G-17 (criteria: PGI≤70 UG/L, PGR≤7.0, G-17≤1 pmol/L or G-17≥15 pmol/L).
• •3. Ability to collect specimens from each time point and provide corresponding clinical information.
• •4. Understand the research plan and voluntarily participate in the study, sign the informed consent form.